Prolonged DMT Infusions could be a Breakthrough for Stroke Patients
Stroke recovery requires stimulating neuroplasticity to heal brain trauma, and prolonged DMT infusions may help speed this process
algernon
Psychedelic Business Spotlight – December 10
This week in psychedelic business news: Wesana Health files a new patent, Silo Pharma is granted a patent, and 2 companies explore a merger.
Psychedelic Business Spotlight: November 5
This week in psychedelic business news: DEA grants Cybin a Schedule I manufacturing license; PharmaTher partners with Revive Therapeutics on microneedle patch technology; Mydecine patents nanotechnology.
Psychedelic Business Spotlight: October 22
This week in psychedelic business news: UK fast tracks DMT for major depressive disorder; Field Trip Health expands its clinical presence in the US; and another psychedelic pharmaceuticals company prepares for the Nasdaq.
Psychedelic Business Spotlight: October 15
This week in psychedelic business news: Cybin inhales; atai Life Sciences expands; DEA grants new psilocybin license; and FDA backs ketamine.
Psychedelic Business Spotlight: September 10, 2021
This week in psychedelic business news: major DMT development for stroke treatment; a propriety psilocybin formulation has potential to treat obesity; two more companies join the OTC Pink Market.
Algernon Pharmaceuticals Shows DMT Can Increase Neuron Growth by 40%
The Vancouver-based drug development company is investigating the use of DMT as a possible treatment for stroke.
End of content
End of content